(Q34152769)

Revision as of 06:31, 9 December 2021 by KrBot (talk | contribs) (‎Set a claim value: title (P1476): Clinical translation of angiogenesis inhibitors)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

English

Clinical translation of angiogenesis inhibitors

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

Clinical translation of angiogenesis inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

2

object named as

Judah Folkman

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Robert Kerbel

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

1 October 2002

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Nature Reviews Cancer

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

727-739

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

https://scigraph.springernature.com/pub.10.1038/nrc905

0 references

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Oncogenes and angiogenesis: signaling three-dimensional tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumor induction of VEGF promoter activity in stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Essential role for oncogenic Ras in tumour maintenance

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Downmodulation of bFGF-binding protein expression following restoration of p53 function

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Inhibition of Cell Motility by Interferon

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Combined effects of angiostatin and ionizing radiation in antitumour therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Special techniques for imaging blood flow to tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Heterogeneous vascular dependence of tumor cell populations

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

A comprehensive system to explore p53 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Growth of a local tumor exerts a specific inhibitory effect on progression of lung metastases

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Secreted cathepsin L generates endostatin from collagen XVIII

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Analysis of experimental antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Treatment of non-small-cell lung cancer with prolonged oral etoposide

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea 2

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiogenesis-dependent diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Involvement of platelets in tumour angiogenesis?

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Cellular markers that distinguish the phases of hemangioma during infancy and childhood

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Successful treatment of an angiogenic disease

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Butyrate in the treatment of sickle cell disease and β-thalassemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Hemangioendothelioma: successful therapy with interferon-alpha: a study in Association with the Italian Pediatric Haematology/Oncology Society (AIEOP)

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Local endostatin treatment of gliomas administered by microencapsulated producer cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Measurement of the grade of vascularisation in histological tumour tissue sections

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiostatin binds ATP synthase on the surface of human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Oncogenes as inducers of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

c-fos is required for malignant progression of skin tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

mAngiogenin-3, a target gene of oncoprotein E2a-Pbx1, encodes a new angiogenic member of the angiogenin family

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

31 March 2020

Concomitant Tumor Immunity and the Resistance to a Second Tumor Challenge

1 reference

https://api.crossref.org/works/10.1038%2FNRC905

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34152769&oldid=1540842286"